Valuation: Exagen Inc.

Market Cap 120M 105M 97.71M 89.87M 169M 11.58B 172M 1.17B 456M 5.65B 449M 439M 19.6B P/E 2026 *
-7.17x
P/E 2027 * -9.71x
Enterprise Value 120M 105M 97.71M 89.87M 169M 11.58B 172M 1.17B 456M 5.65B 449M 439M 19.6B EV / Sales 2026 *
1.67x
EV / Sales 2027 * 1.51x
Free-Float
57.84%
Yield 2026 *
-
Yield 2027 * -
1 day-4.55%
1 week+8.43%
Current month+2.37%
1 month+5.31%
3 months+76.30%
6 months+7.94%
Current year-21.71%
1 week 4.42
Extreme 4.42
5.11
1 month 4.05
Extreme 4.05
5.11
Current year 2.59
Extreme 2.59
6.75
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.9
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 2022-10-16
Director of Finance/CFO 57 2024-08-31
Chief Tech/Sci/R&D Officer - 2025-06-22
Director TitleAgeSince
Chairman 72 2023-01-18
Director/Board Member 63 2019-07-29
Director/Board Member 56 2021-06-16
Date Insider Type Main position Quantity % Market Cap.
6/9/26 Free

Director

37,500 0.1552%
6/9/26 Free

Director

37,500 0.1552%
6/9/26 Free

Director

37,500 0.1552%
Change 5-day change 1-year change 3-year change Capi.($)
-4.55%+8.43%-34.07%+83.89% 120M
+0.14%-2.16%+88.22%+467.46% 37.91B
+1.98%+4.80%+10.94%+35.71% 23.86B
+2.02%-3.02%-25.07%-40.23% 7.16B
+1.46%-0.70%+10.30%+79.16% 4.8B
+4.27%+4.26%+13.76%+49.95% 2.91B
-2.45%-3.17%-24.53%+690.10% 1.88B
-2.18%-4.95%-10.86%-62.78% 1.81B
-0.07%-2.05%+122.90%-14.36% 1.85B
+6.17%-1.39%+15.62%+4.40% 1.77B
Average +0.73%+0.79%+16.72%+129.33% 8.41B
Weighted average by Cap. +1.11%-0.56%+44.01%+237.69%

Financials

2026 *2027 *
Net sales 71.67M 63.04M 58.56M 53.86M 101M 6.94B 103M 700M 273M 3.39B 269M 263M 11.75B 79.39M 69.82M 64.86M 59.66M 112M 7.69B 114M 776M 303M 3.75B 298M 292M 13.01B
Net income -16.93M -14.89M -13.84M -12.72M -23.86M -1.64B -24.29M -165M -64.53M -800M -63.57M -62.2M -2.77B -13M -11.43M -10.62M -9.77M -18.32M -1.26B -18.65M -127M -49.54M -614M -48.8M -47.75M -2.13B
Net Debt - -
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
26-07-24 US$4.760 -3.84% 28,357
26-07-23 US$4.950 +0.20% 328,270
26-07-22 US$4.940 +1.65% 163,345
26-07-21 US$4.860 +3.85% 234,357
26-07-20 US$4.680 +6.61% 513,219
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.950USD
Average target price
8.571USD
Spread / Average Target
+73.16%

Quarterly revenue - Rate of surprise